How much aged garlic to lower blood pressure

Journal Article

Karin Ried

1National Institute of Integrative Medicine, Melbourne, Australia

Author disclosures: K Ried, no conflicts of interest. K Ried received travel sponsorship from Wakunaga of America Co. Ltd. to attend the 2014 International Garlic Symposium.

Search for other works by this author on:

1

Published in a supplement to The Journal of Nutrition. Presented at the conference "2014 International Garlic Symposium: Role of Garlic in Cardiovascular Disease Prevention, Metabolic Syndrome, and Immunology," held 4–6 March 2014 at St. Regis Monarch Beach Resort in Dana Point, CA. This supplement is dedicated to our colleague and friend John A Milner. His dedication to good science and his voice for nutrition are remembered and sorely missed. The symposium was sponsored by the University of California, Los Angeles School of Medicine and the University of Florida and co-sponsored by the American Botanical Council; the American Herbal Products Association; the ASN; the Japanese Society for Food Factors; the Japan Society for Bioscience, Biotechnology, and Agrochemistry; the Japan Society of Nutrition and Food Science; and the Natural Products Association. The symposium was supported by Agencias Motta S.A.; Bionam; Eco-Nutraceuticos; Healthy U 2000 Ltd.; Magna; Mannavita Bvba; MaxiPharma; Medica Nord A.S.; Nature's Farm Pte. Ltd.; Nature Valley W.L.L.; Organic Health Ltd.; Oy Valioravinto Ab; Purity Life Health Products L.P.; PT Nutriprima Jayasakti; Vitaco Health Ltd.; Vitae Natural Nutrition; Sanofi Consumer Health Care; Wakunaga Pharmaceutical Co., Ltd.; and Wakunaga of America Co., Ltd. The Chair of the conference and Scientific Program Coordinator for the supplement publication was Matthew J Budoff, Harbor-UCLA Medical Center, Torrance, CA. Scientific Program Coordinator disclosures: MJ Budoff has been awarded research grants from Wakunaga of America Co., Ltd., and received an honorarium for serving as Chair of the conference. Vice-Chair and Supplement Coordinator for the supplement publication was Susan S Percival, University of Florida, Gainesville, FL. Supplement Coordinator disclosures: SS Percival has been awarded research grants from Wakunaga of America Co., Ltd., and received an honorarium for serving as Vice-Chair of the conference. Publication costs for this supplement were defrayed in part by the payment of page charges. This publication must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact. The opinions expressed in this publication are those of the authors and are not attributable to the sponsors or the publisher, Editor, or Editorial Board of The Journal of Nutrition.

Author Notes

Revision received:

10 October 2014

Accepted:

07 November 2014

Published:

13 January 2016

  • How much aged garlic to lower blood pressure
    PDF
  • Split View
    • Article contents
    • Figures & tables
    • Video
    • Audio
    • Supplementary Data
  • Cite

    Cite

    Karin Ried, Garlic Lowers Blood Pressure in Hypertensive Individuals, Regulates Serum Cholesterol, and Stimulates Immunity: An Updated Meta-analysis and Review, The Journal of Nutrition, Volume 146, Issue 2, February 2016, Pages 389S–396S, https://doi.org/10.3945/jn.114.202192

    Close

    • Email
    • Twitter
    • Facebook
    • More

Close

Navbar Search Filter Microsite Search Term Search

Abstract

Background: Garlic has been shown to have cardiovascular protective and immunomodulatory properties.

Objectives: We updated a previous meta-analysis on the effect of garlic on blood pressure and reviewed the effect of garlic on cholesterol and immunity.

Methods: We searched the Medline database for randomized controlled trials (RCTs) published between 1955 and December 2013 on the effect of garlic preparations on blood pressure. In addition, we reviewed the effect of garlic on cholesterol and immunity.

Results: Our updated meta-analysis on the effect of garlic on blood pressure, which included 20 trials with 970 participants, showed a mean ± SE decrease in systolic blood pressure (SBP) of 5.1 ± 2.2 mm Hg (P < 0.001) and a mean ± SE decrease in diastolic blood pressure (DBP) of 2.5 ± 1.6 mm Hg (P < 0.002) compared with placebo. Subgroup analysis of trials in hypertensive subjects (SBP/DBP ≥140/90 mm Hg) at baseline revealed a larger significant reduction in SBP of 8.7 ± 2.2 mm Hg (P < 0.001; n = 10) and in DBP of 6.1 ± 1.3 mm Hg (P < 0.001; n = 6). A previously published meta-analysis on the effect of garlic on blood lipids, which included 39 primary RCTs and 2300 adults treated for a minimum of 2 wk, suggested garlic to be effective in reducing total and LDL cholesterol by 10% if taken for >2 mo by individuals with slightly elevated concentrations [e.g., total cholesterol >200 mg/dL (>5.5 mmol/L)]. Garlic has immunomodulating effects by increasing macrophage activity, natural killer cells, and the production of T and B cells. Clinical trials have shown garlic to significantly reduce the number, duration, and severity of upper respiratory infections.

Conclusions: Our review suggests that garlic supplements have the potential to lower blood pressure in hypertensive individuals, to regulate slightly elevated cholesterol concentrations, and to stimulate the immune system. Garlic supplements are highly tolerated and may be considered as a complementary treatment option for hypertension, slightly elevated cholesterol, and stimulation of immunity. Future long-term trials are needed to elucidate the effect of garlic on cardiovascular morbidity and mortality.

Introduction

Traditionally, garlic has a long history as a remedy for improving strength, reducing fatigue, and increasing immunity both in prevention and treatment of infectious diseases and gastrointestinal function (1). In modern times, garlic has also been linked to improved cardiovascular health, including blood pressure, cholesterol, and other cardiovascular markers (2, 3). We updated our previously published meta-analysis on the effect of garlic on blood pressure (2) with the inclusion of several more recent trials, reviewed our meta-analysis on the effect of garlic on cholesterol, and summarized the effect of garlic on the immune system.

Effect of garlic on blood pressure.

High blood pressure is an important risk factor for cardiovascular disease and is attributed to an estimated 70% of heart attacks, strokes, and chronic heart failure, leading to 37% of cardiovascular deaths in Western countries and 13.5% globally (4, 5).3 Epidemiologic studies describe a continuous association between blood pressure and cardiovascular disease risk, suggesting a reduction in high systolic blood pressure (SBP; >140 mm Hg) by 20 mm Hg and a reduction in high diastolic blood pressure (DBP; >90 mm Hg) by 10 mm Hg to be associated with a 50% risk reduction in developing cardiovascular disease (6). Hypertension affects ∼30% of adults in Western countries, with 68 million adults in the United States alone (7). Although management of blood pressure in family practice has increased in the past 20 y, a large proportion of adults (23%) have uncontrolled blood pressure (7, 8), 9% have untreated blood pressure, and half of those treated do not achieve optimal control (7, 9).

Current medical treatment of hypertension.

Approximately 40% of hypertensive patients can achieve the target blood pressure of <140/90 mm Hg with monotherapy, independent of the type of antihypertensive medication used. Approximately 40% require combination therapy with 2 agents, and 20% need to take ≥3 antihypertensive medications to achieve blood pressure control (10). In Australia, for example, the most commonly prescribed class of antihypertensive medications (56%) are angiotensin-converting enzyme inhibitors, followed by angiotensin II receptor antagonists (27%), calcium channel blockers, diuretics, and β-blockers (11). Adverse reactions from antihypertensive medications may occur in a significant number of patients and are more likely when multiple drugs are prescribed (12). Adverse reactions include fatigue, dizziness, cough, headache, myalgia, angioedema, renal impairment, gastrointestinal upset, and hyperglycemia (12).

Garlic supplements have shown promise in lowering blood pressure in several meta-analyses (2, 13, 14), and the blood pressure–lowering action of garlic is biologically plausible. Garlic contains a number of active sulfur compounds (15) that have been reported to modulate endothelium-relaxing and -constricting factors, leading to blood pressure reduction. Specifically, garlic has been shown to stimulate the production of NO and hydrogen sulphide (H2S), both gasotransmitters leading to vasorelaxation (16–18). In addition, others reported that garlic reduced the production of the vasoconstricting factors endothelin 1 and angiotensin II (19, 20). This meta-analysis and review updates our previously published meta-analyses on the effect of garlic on blood pressure with the inclusion of recent trials.

Methods

We included trials selected in previous meta-analyses by Silagy and Neil (13), Reinhart et al. (14), and Ried et al. (2) and extended the search by using the search terms “garlic” and “hypertension” or “blood pressure” in Medline for published trials between 2008 and 2013. We included studies with placebo control groups, that used garlic-only supplements, and that reported mean SBP and/or DBP and SDs (Table 1).

TABLE 1

Characteristics of trials included in the meta-analysis of the effect of garlic on blood pressure1

Baseline mean SBP/DBP, mm Hg
Authors, year (reference)Garlic/control, nStudy designGarlic typeBrand2Dosage, mg/dDosage of active ingredient, mg/dDuration, wkGarlicControl
Kandziora, 1988 (22)  20/20  GP  Kwai  600  7.8, alliin  12  174/99  175/98 
Auer et al., 1990 (23)  24/23  GP  Kwai  600  7.8, alliin  12  171/102  161/97 
Vorberg and Schneider, 1990 (24)  20/20  GP  Kwai  900  11.7, alliin  16  144.5/91  144/88 
Holzgartner et al., 1992 (25)  47/47  GP  Kwai  900  11.7, alliin  12  143/83  141/82 
Jain et al., 1993 (26)  20/22  GP  Kwai  900  11.7, alliin  12  129/82  128/83 
DeASantos and Gruenwald, 1993 (27)  25/27  GP  Kwai  900  11.7, alliin  24  143/89  144/89 
Kiesewetter et al., 1993 (28)  32/32  GP  Kwai  800  10.4, alliin  12  NR/85  NR/83 
Saradeth et al., 1994 (29)  31/37  GP  Kwai  600  7.8, alliin  15  125/81  125/82 
Simons et al., 1995 (30)  28/28  GP  Kwai  900  11.7, alliin  12  127/80  127/80 
Steiner et al., 1996 (31)  41/41  AGE  Kyolic  2400  NR  23  134/84  134/85 
Adler and Holub, 1997 (32)  12/11  GP  Kwai  900  11.7, alliin  12  123/83  118/79 
Isaacsohn et al., 1998 (33)  28/22  GP  Kwai  900  11.7, alliin  12  119/73  123/72 
Zhang et al., 2000 (34)  14/13  GO  Cardiomax  12.3  NR  16  114/72  109/64 
Williams et al., 2005 (35)  15/15  AGE  Kyolic  2400  2, SAC  132/82  132/82 
Macan et al., 2006 (36)  22/26  AGE  Kyolic  3050  14.7, SAC  12  122/74  127/82 
Sobenin et al., 2008 (37)  23/19  GP  Allicor  600  7.8, allicin pt  12  143/89  140/88 
Sobenin et al., 2009 (38)  G1: 30/P: 20  GP  G1: Allicor  G1: 600  G1: 7.8, allicin  G1: 156/96  150/94 
  G2:18  GP  G2: Allicor  G2: 2400  G2: 31.2, allicin  G2: 153/95  150/94 
  G3: 16  GP  G3: Kwai  G3: 900  G3: 11.7, alliin  G3: 152/96  150/94 
Ried et al., 2010 (39)  25/25  AGE  Kyolic  960  2.4, SAC  12  135/74  141/76 
Ried et al., 2013 (40)  G1:18/P: 17  AGE  Kyolic  G1: 240  G1: 0.6, SAC  12  G1: 151/77  149/76 
  G2:20  AGE  Kyolic  G2: 480  G2: 1.2, SAC  12  G2: 149/76  149/76 
  G3: 19  AGE  Kyolic  G3: 960  G3: 2.4, SAC  12  G3: 149 /76  149/76 
Nakasone et al., 2013 (41)  HT: 23/24  GPjpn  Dentou-ninniku-ranwo  188  NR  12  HT: 142/91  HT: 142/92 
  NT: 16/18  GPjpn  Dentou-ninniku-ranwo  188  NR  12  NT: 134/83  NT: 134/82 

Baseline mean SBP/DBP, mm Hg
Authors, year (reference)Garlic/control, nStudy designGarlic typeBrand2Dosage, mg/dDosage of active ingredient, mg/dDuration, wkGarlicControl
Kandziora, 1988 (22)  20/20  GP  Kwai  600  7.8, alliin  12  174/99  175/98 
Auer et al., 1990 (23)  24/23  GP  Kwai  600  7.8, alliin  12  171/102  161/97 
Vorberg and Schneider, 1990 (24)  20/20  GP  Kwai  900  11.7, alliin  16  144.5/91  144/88 
Holzgartner et al., 1992 (25)  47/47  GP  Kwai  900  11.7, alliin  12  143/83  141/82 
Jain et al., 1993 (26)  20/22  GP  Kwai  900  11.7, alliin  12  129/82  128/83 
DeASantos and Gruenwald, 1993 (27)  25/27  GP  Kwai  900  11.7, alliin  24  143/89  144/89 
Kiesewetter et al., 1993 (28)  32/32  GP  Kwai  800  10.4, alliin  12  NR/85  NR/83 
Saradeth et al., 1994 (29)  31/37  GP  Kwai  600  7.8, alliin  15  125/81  125/82 
Simons et al., 1995 (30)  28/28  GP  Kwai  900  11.7, alliin  12  127/80  127/80 
Steiner et al., 1996 (31)  41/41  AGE  Kyolic  2400  NR  23  134/84  134/85 
Adler and Holub, 1997 (32)  12/11  GP  Kwai  900  11.7, alliin  12  123/83  118/79 
Isaacsohn et al., 1998 (33)  28/22  GP  Kwai  900  11.7, alliin  12  119/73  123/72 
Zhang et al., 2000 (34)  14/13  GO  Cardiomax  12.3  NR  16  114/72  109/64 
Williams et al., 2005 (35)  15/15  AGE  Kyolic  2400  2, SAC  132/82  132/82 
Macan et al., 2006 (36)  22/26  AGE  Kyolic  3050  14.7, SAC  12  122/74  127/82 
Sobenin et al., 2008 (37)  23/19  GP  Allicor  600  7.8, allicin pt  12  143/89  140/88 
Sobenin et al., 2009 (38)  G1: 30/P: 20  GP  G1: Allicor  G1: 600  G1: 7.8, allicin  G1: 156/96  150/94 
  G2:18  GP  G2: Allicor  G2: 2400  G2: 31.2, allicin  G2: 153/95  150/94 
  G3: 16  GP  G3: Kwai  G3: 900  G3: 11.7, alliin  G3: 152/96  150/94 
Ried et al., 2010 (39)  25/25  AGE  Kyolic  960  2.4, SAC  12  135/74  141/76 
Ried et al., 2013 (40)  G1:18/P: 17  AGE  Kyolic  G1: 240  G1: 0.6, SAC  12  G1: 151/77  149/76 
  G2:20  AGE  Kyolic  G2: 480  G2: 1.2, SAC  12  G2: 149/76  149/76 
  G3: 19  AGE  Kyolic  G3: 960  G3: 2.4, SAC  12  G3: 149 /76  149/76 
Nakasone et al., 2013 (41)  HT: 23/24  GPjpn  Dentou-ninniku-ranwo  188  NR  12  HT: 142/91  HT: 142/92 
  NT: 16/18  GPjpn  Dentou-ninniku-ranwo  188  NR  12  NT: 134/83  NT: 134/82 

1

AGE, aged garlic extract; c, crossover trial; G1–3, garlic groups 1–3; GO, garlic oil; GP, garlic powder; GPjpn, Japanese garlic powder containing egg yolk; HT, hypertensive group; NR, not reported; NT, normotensive group; p, parallel trial; P, placebo group; pt, potential; SAC, S-allylcysteine; SBP/DBP, systolic blood pressure/diastolic blood pressure.

2

Manufacturers' details of brands: Allicor: INAT-Farma, Moscow, Russia; Cardiomax: Seven Seas, Hull, United Kingdom; Dentou-ninniku-ranwo: Kenkoukazou Inc, Kagoshima, Japan; Kwai: Lichtwer Pharma GmbH, Berlin, Germany; Kyolic: Wakunaga of America Co Ltd, Mission Viejo, USA & Wakunaga Pharmaceuticals Co Ltd, Hiroshima, Japan.

TABLE 1

Characteristics of trials included in the meta-analysis of the effect of garlic on blood pressure1

Baseline mean SBP/DBP, mm Hg
Authors, year (reference)Garlic/control, nStudy designGarlic typeBrand2Dosage, mg/dDosage of active ingredient, mg/dDuration, wkGarlicControl
Kandziora, 1988 (22)  20/20  GP  Kwai  600  7.8, alliin  12  174/99  175/98 
Auer et al., 1990 (23)  24/23  GP  Kwai  600  7.8, alliin  12  171/102  161/97 
Vorberg and Schneider, 1990 (24)  20/20  GP  Kwai  900  11.7, alliin  16  144.5/91  144/88 
Holzgartner et al., 1992 (25)  47/47  GP  Kwai  900  11.7, alliin  12  143/83  141/82 
Jain et al., 1993 (26)  20/22  GP  Kwai  900  11.7, alliin  12  129/82  128/83 
DeASantos and Gruenwald, 1993 (27)  25/27  GP  Kwai  900  11.7, alliin  24  143/89  144/89 
Kiesewetter et al., 1993 (28)  32/32  GP  Kwai  800  10.4, alliin  12  NR/85  NR/83 
Saradeth et al., 1994 (29)  31/37  GP  Kwai  600  7.8, alliin  15  125/81  125/82 
Simons et al., 1995 (30)  28/28  GP  Kwai  900  11.7, alliin  12  127/80  127/80 
Steiner et al., 1996 (31)  41/41  AGE  Kyolic  2400  NR  23  134/84  134/85 
Adler and Holub, 1997 (32)  12/11  GP  Kwai  900  11.7, alliin  12  123/83  118/79 
Isaacsohn et al., 1998 (33)  28/22  GP  Kwai  900  11.7, alliin  12  119/73  123/72 
Zhang et al., 2000 (34)  14/13  GO  Cardiomax  12.3  NR  16  114/72  109/64 
Williams et al., 2005 (35)  15/15  AGE  Kyolic  2400  2, SAC  132/82  132/82 
Macan et al., 2006 (36)  22/26  AGE  Kyolic  3050  14.7, SAC  12  122/74  127/82 
Sobenin et al., 2008 (37)  23/19  GP  Allicor  600  7.8, allicin pt  12  143/89  140/88 
Sobenin et al., 2009 (38)  G1: 30/P: 20  GP  G1: Allicor  G1: 600  G1: 7.8, allicin  G1: 156/96  150/94 
  G2:18  GP  G2: Allicor  G2: 2400  G2: 31.2, allicin  G2: 153/95  150/94 
  G3: 16  GP  G3: Kwai  G3: 900  G3: 11.7, alliin  G3: 152/96  150/94 
Ried et al., 2010 (39)  25/25  AGE  Kyolic  960  2.4, SAC  12  135/74  141/76 
Ried et al., 2013 (40)  G1:18/P: 17  AGE  Kyolic  G1: 240  G1: 0.6, SAC  12  G1: 151/77  149/76 
  G2:20  AGE  Kyolic  G2: 480  G2: 1.2, SAC  12  G2: 149/76  149/76 
  G3: 19  AGE  Kyolic  G3: 960  G3: 2.4, SAC  12  G3: 149 /76  149/76 
Nakasone et al., 2013 (41)  HT: 23/24  GPjpn  Dentou-ninniku-ranwo  188  NR  12  HT: 142/91  HT: 142/92 
  NT: 16/18  GPjpn  Dentou-ninniku-ranwo  188  NR  12  NT: 134/83  NT: 134/82 

Baseline mean SBP/DBP, mm Hg
Authors, year (reference)Garlic/control, nStudy designGarlic typeBrand2Dosage, mg/dDosage of active ingredient, mg/dDuration, wkGarlicControl
Kandziora, 1988 (22)  20/20  GP  Kwai  600  7.8, alliin  12  174/99  175/98 
Auer et al., 1990 (23)  24/23  GP  Kwai  600  7.8, alliin  12  171/102  161/97 
Vorberg and Schneider, 1990 (24)  20/20  GP  Kwai  900  11.7, alliin  16  144.5/91  144/88 
Holzgartner et al., 1992 (25)  47/47  GP  Kwai  900  11.7, alliin  12  143/83  141/82 
Jain et al., 1993 (26)  20/22  GP  Kwai  900  11.7, alliin  12  129/82  128/83 
DeASantos and Gruenwald, 1993 (27)  25/27  GP  Kwai  900  11.7, alliin  24  143/89  144/89 
Kiesewetter et al., 1993 (28)  32/32  GP  Kwai  800  10.4, alliin  12  NR/85  NR/83 
Saradeth et al., 1994 (29)  31/37  GP  Kwai  600  7.8, alliin  15  125/81  125/82 
Simons et al., 1995 (30)  28/28  GP  Kwai  900  11.7, alliin  12  127/80  127/80 
Steiner et al., 1996 (31)  41/41  AGE  Kyolic  2400  NR  23  134/84  134/85 
Adler and Holub, 1997 (32)  12/11  GP  Kwai  900  11.7, alliin  12  123/83  118/79 
Isaacsohn et al., 1998 (33)  28/22  GP  Kwai  900  11.7, alliin  12  119/73  123/72 
Zhang et al., 2000 (34)  14/13  GO  Cardiomax  12.3  NR  16  114/72  109/64 
Williams et al., 2005 (35)  15/15  AGE  Kyolic  2400  2, SAC  132/82  132/82 
Macan et al., 2006 (36)  22/26  AGE  Kyolic  3050  14.7, SAC  12  122/74  127/82 
Sobenin et al., 2008 (37)  23/19  GP  Allicor  600  7.8, allicin pt  12  143/89  140/88 
Sobenin et al., 2009 (38)  G1: 30/P: 20  GP  G1: Allicor  G1: 600  G1: 7.8, allicin  G1: 156/96  150/94 
  G2:18  GP  G2: Allicor  G2: 2400  G2: 31.2, allicin  G2: 153/95  150/94 
  G3: 16  GP  G3: Kwai  G3: 900  G3: 11.7, alliin  G3: 152/96  150/94 
Ried et al., 2010 (39)  25/25  AGE  Kyolic  960  2.4, SAC  12  135/74  141/76 
Ried et al., 2013 (40)  G1:18/P: 17  AGE  Kyolic  G1: 240  G1: 0.6, SAC  12  G1: 151/77  149/76 
  G2:20  AGE  Kyolic  G2: 480  G2: 1.2, SAC  12  G2: 149/76  149/76 
  G3: 19  AGE  Kyolic  G3: 960  G3: 2.4, SAC  12  G3: 149 /76  149/76 
Nakasone et al., 2013 (41)  HT: 23/24  GPjpn  Dentou-ninniku-ranwo  188  NR  12  HT: 142/91  HT: 142/92 
  NT: 16/18  GPjpn  Dentou-ninniku-ranwo  188  NR  12  NT: 134/83  NT: 134/82 

1

AGE, aged garlic extract; c, crossover trial; G1–3, garlic groups 1–3; GO, garlic oil; GP, garlic powder; GPjpn, Japanese garlic powder containing egg yolk; HT, hypertensive group; NR, not reported; NT, normotensive group; p, parallel trial; P, placebo group; pt, potential; SAC, S-allylcysteine; SBP/DBP, systolic blood pressure/diastolic blood pressure.

2

Manufacturers' details of brands: Allicor: INAT-Farma, Moscow, Russia; Cardiomax: Seven Seas, Hull, United Kingdom; Dentou-ninniku-ranwo: Kenkoukazou Inc, Kagoshima, Japan; Kwai: Lichtwer Pharma GmbH, Berlin, Germany; Kyolic: Wakunaga of America Co Ltd, Mission Viejo, USA & Wakunaga Pharmaceuticals Co Ltd, Hiroshima, Japan.

Changes in mean SBP or DBP in garlic and control groups before and after intervention were entered into the meta-analysis by using a random-effects model in Review Manager, version 5.2 (21). In addition, we performed a subgroup meta-analysis of trials in hypertensive subjects at the start of treatment (mean SBP ≥140 mm Hg or mean DBP ≥90 mm Hg) and a subgroup analysis of trials in normotensive subjects at the start of treatment (mean SBP <140 mm Hg or mean DBP <90 mm Hg).

Results

Meta-analysis

A total of 20 trials in >900 participants were identified as meeting the inclusion criteria (22–41), including 5 recent trials (37–41) that were not included in previous meta-analyses (2, 13, 14). Two trials (39, 41) included hypertensive and normotensive participants in the garlic and placebo groups. We undertook a meta-analysis that included all patients as well as a subgroup meta-analysis by baseline blood pressure (hypertensive or normotensive at baseline). Two trials (38, 40) featured 4-group, parallel, randomized controlled trials, with 3 active garlic groups of different dosages and a placebo group. In the main meta-analysis, we included only one active group compared with placebo from each of the 2 trials: the Allicor (INAT-Farma, Moscow, Russia) 400-mg group (38) and the garlic 2-capsule group (40). In addition, we tested the other active garlic groups of the 2 trials in sensitivity analysis.

Meta-analyses of all 20 trials (25 trial arms) suggested that garlic supplements significantly lower SBP by a mean (±SE) difference of 5.1 ± 2.2 mm Hg (P < 0.001; n = 19) and DBP by a mean difference of 2.6 ± 1.6 mm Hg (P < 0.001; n = 20) (Figures 1 and 2). Subgroup meta-analysis of trials and trial arms involving hypertensive participants revealed a larger significant reduction in SBP (mean difference for SBPhypertensive: −8.6 ± 2.2 mm Hg; P < 0.001; n = 10) and DBP (mean difference for DBPhypertensive: −6.1 ± 1.3 mm Hg; P < 0.001; n = 6) (Figures 3 and 4). In contrast, subgroup meta-analyses of trials involving participants with blood pressure in the prehypertensive and normal range at baseline (SBP/DBP <140/90 mm Hg) did not reveal a significant effect (mean difference for SBPnormotensive: −1.5 ± 1.9 mm Hg; n = 11; mean difference for DBPnormotensive: −0.4 ± 1.2 mm Hg; n = 14).

FIGURE 1

How much aged garlic to lower blood pressure

Forest plot showing the effect of garlic on systolic blood pressure; n = 19 trials (25 trial arms) including only 1 of 3 trial arms in 2 trials that tested different dosages of garlic compared with placebo [Sobenin 2009 (38): a2400 group; Ried 2013 (40): g2 group]. Other trial arms were tested in sensitivity analyses. Values are weighted mean differences (95% CIs) comparing changes in systolic blood pressure over time between treatment and control groups. a600, Allicor-600 mg; a2400, Allicor-2400 mg; g1, g2, g4, garlic 1-, 2-, 4-capsule group; HTSG, hypertensive subgroup; IV, inverse variance; k900, Kwai-900 mg; NTSG, normotensive subgroup.

FIGURE 2

How much aged garlic to lower blood pressure

Forest plot showing the effect of garlic on diastolic blood pressure; n = 20 trials (25 trial arms). Values are weighted mean differences (95% CIs) comparing changes in diastolic blood pressure over time between treatment and control groups. a600, Allicor-600 mg; a2400, Allicor-2400 mg; g1, g2, g4, garlic 1-, 2-, 4-capsule group; HTSG, hypertensive subgroup; IV, inverse variance; k900, Kwai-900 mg; NTSG, normotensive subgroup.

FIGURE 3

How much aged garlic to lower blood pressure

Forest plot showing the effect of garlic on systolic blood pressure in hypertensive subjects. Values are weighted mean differences (95% CIs) comparing changes in systolic blood pressure over time between treatment and control groups. a600, Allicor-600 mg; a2400, Allicor-2400 mg; g1, g2, g4, garlic 1-, 2-, 4-capsule group; HTSG, hypertensive subgroup; IV, inverse variance; k900, Kwai-900 mg; SBP, systolic blood pressure.

FIGURE 4

How much aged garlic to lower blood pressure

Forest plot showing the effect of garlic on diastolic blood pressure in hypertensive subjects. Values are weighted mean differences (95% CIs) comparing changes in diastolic blood pressure over time between treatment and control groups. a600, Allicor-600 mg; a2400, Allicor-2400 mg; DBP, diastolic blood pressure; HTSG, hypertensive subgroup; IV, inverse variance; k900, Kwai-900 mg.

The majority of trials included in the meta-analysis used standard garlic powder (GP) supplements (n = 13), 5 trials used aged garlic extract (AGE), 1 trial used garlic oil (GO), and 1 trial used an egg yolk–enriched GP. Results of subgroup analysis by type of garlic were similar between GP (n = 13) and AGE (n = 5) (Table 2). In addition, we conducted sensitivity analyses excluding the trial by Nakasone et al. (41), because this trial used a modified GP, and the influence of the egg yolk on blood pressure cannot be ruled out. These and other sensitivity analyses that used alternate trial arms with different dosages of garlic in Sobenin et al. (38) and Ried et al. (38) did not change the results appreciably (Table 2).

TABLE 2

Subgroup and sensitivity analyses1

SBP/DBP
SubgroupAuthors, year (reference)GroupTrials, nSubjects, nSBPDBP
By type of garlic  —  All19/20  908/940  −5.1 ± 2.2  −2.6 ± 1.6 
  —  GP  12/13  576/640  −5.8 ± 3.2  −3.2 ± 2.0 
  —  AGE  5/5  233  −4.1 ± 3.1  0.02 ± 2.9 
Sensitivity analysis             
With trial arm a600  Sobenin et al., 2009 (38)  All  19/20  920/952  −4.9 ± 2.0  −2.6 ± 1.7 
With trial arm k900  Sobenin et al., 2009 (38)  All  19/20  906/938  −4.7 ± 2.0  −2.4 ± 1.7 
With trial arm g1  Ried et al., 2013 (40)  All  19/20  905/941  −4.7 ± 2.2  −2.5 ± 1.7 
With trial arm g4  Ried et al., 2013 (40)  All  19/20  905/942  −4.9 ± 2.2  −2.5 ± 1.8 
Excluding trial  Nakasone et al., 2013 (41)  All  18/19  836/900  −5.2 ± 2.4  −2.5 ± 1.7 

SBP/DBP
SubgroupAuthors, year (reference)GroupTrials, nSubjects, nSBPDBP
By type of garlic  —  All19/20  908/940  −5.1 ± 2.2  −2.6 ± 1.6 
  —  GP  12/13  576/640  −5.8 ± 3.2  −3.2 ± 2.0 
  —  AGE  5/5  233  −4.1 ± 3.1  0.02 ± 2.9 
Sensitivity analysis             
With trial arm a600  Sobenin et al., 2009 (38)  All  19/20  920/952  −4.9 ± 2.0  −2.6 ± 1.7 
With trial arm k900  Sobenin et al., 2009 (38)  All  19/20  906/938  −4.7 ± 2.0  −2.4 ± 1.7 
With trial arm g1  Ried et al., 2013 (40)  All  19/20  905/941  −4.7 ± 2.2  −2.5 ± 1.7 
With trial arm g4  Ried et al., 2013 (40)  All  19/20  905/942  −4.9 ± 2.2  −2.5 ± 1.8 
Excluding trial  Nakasone et al., 2013 (41)  All  18/19  836/900  −5.2 ± 2.4  −2.5 ± 1.7 

1

Values are means ± SEs unless otherwise indicated. a600, Allicor-600 mg group; AGE, aged garlic extract; DBP, diastolic blood pressure; g1, garlic 1-capsule group; g4, garlic 4-capsule group; GP, garlic powder; k900, Kwai-900 mg group; SBP, systolic blood pressure.

2

Includes the a2400 (Allicor-2400 mg) arm of trial in reference 38 and the g2 (garlic 2)-capsule group of trial in reference 40.

TABLE 2

Subgroup and sensitivity analyses1

SBP/DBP
SubgroupAuthors, year (reference)GroupTrials, nSubjects, nSBPDBP
By type of garlic  —  All19/20  908/940  −5.1 ± 2.2  −2.6 ± 1.6 
  —  GP  12/13  576/640  −5.8 ± 3.2  −3.2 ± 2.0 
  —  AGE  5/5  233  −4.1 ± 3.1  0.02 ± 2.9 
Sensitivity analysis             
With trial arm a600  Sobenin et al., 2009 (38)  All  19/20  920/952  −4.9 ± 2.0  −2.6 ± 1.7 
With trial arm k900  Sobenin et al., 2009 (38)  All  19/20  906/938  −4.7 ± 2.0  −2.4 ± 1.7 
With trial arm g1  Ried et al., 2013 (40)  All  19/20  905/941  −4.7 ± 2.2  −2.5 ± 1.7 
With trial arm g4  Ried et al., 2013 (40)  All  19/20  905/942  −4.9 ± 2.2  −2.5 ± 1.8 
Excluding trial  Nakasone et al., 2013 (41)  All  18/19  836/900  −5.2 ± 2.4  −2.5 ± 1.7 

SBP/DBP
SubgroupAuthors, year (reference)GroupTrials, nSubjects, nSBPDBP
By type of garlic  —  All19/20  908/940  −5.1 ± 2.2  −2.6 ± 1.6 
  —  GP  12/13  576/640  −5.8 ± 3.2  −3.2 ± 2.0 
  —  AGE  5/5  233  −4.1 ± 3.1  0.02 ± 2.9 
Sensitivity analysis             
With trial arm a600  Sobenin et al., 2009 (38)  All  19/20  920/952  −4.9 ± 2.0  −2.6 ± 1.7 
With trial arm k900  Sobenin et al., 2009 (38)  All  19/20  906/938  −4.7 ± 2.0  −2.4 ± 1.7 
With trial arm g1  Ried et al., 2013 (40)  All  19/20  905/941  −4.7 ± 2.2  −2.5 ± 1.7 
With trial arm g4  Ried et al., 2013 (40)  All  19/20  905/942  −4.9 ± 2.2  −2.5 ± 1.8 
Excluding trial  Nakasone et al., 2013 (41)  All  18/19  836/900  −5.2 ± 2.4  −2.5 ± 1.7 

1

Values are means ± SEs unless otherwise indicated. a600, Allicor-600 mg group; AGE, aged garlic extract; DBP, diastolic blood pressure; g1, garlic 1-capsule group; g4, garlic 4-capsule group; GP, garlic powder; k900, Kwai-900 mg group; SBP, systolic blood pressure.

2

Includes the a2400 (Allicor-2400 mg) arm of trial in reference 38 and the g2 (garlic 2)-capsule group of trial in reference 40.

Table 3 summarizes the results of our updated meta-analysis and earlier meta-analyses on the effect of garlic on blood pressure, illustrating blood pressure status at baseline (hypertensive or normotensive) to be a strong predictor of the magnitude of blood pressure reduction. Side effects of garlic supplements, reported by approximately one-third of participants in the trials, were generally mild and included burping, flatulence, and reflux in the first few weeks of the trial (39, 40). A small percentage of the population (4–6%) may experience more severe gastrointestinal disturbances with therapeutic dosages of garlic supplements (39, 40, 42, 43). The lower tolerance of sulfur-containing foods such as garlic and onion has been linked to genetic variation in detoxification pathways of sulfur-transferase enzymes, as well as inflammatory status, and concentrations of molybdenum and vitamin B-12 (44, 45).

TABLE 3

Comparison of meta-analyses on the effect of garlic on blood pressure1

SBP difference (garlic vs. placebo), mm HgDBP difference (garlic vs. placebo), mm Hg
Authors, year (reference)Trials, nSubjects, nAllHypertensive subgroupNormotensive subgroupTrials, nSubjects, nAllHypertensive subgroupNormotensive subgroup
Silagy and Neil, 1994 (13)  347  −7.7 ± 3.4  —  —  347  −5.0 ± 2.1  —  — 
  87    −11.1 ± 6.1  —  87    −6.5 ± 3.1  — 
Reinhart et al., 2008 (14)  10  444  −3.9 ± 4.4  —  —  10  444  −2.8 ± 2.4  —  — 
  139    −16.3 ± 10.1  —  139  —  −9.3 ± 4.0  — 
  305    —  −0.5 ± 2.6  305  —  —  −0.9 ± 1.8 
Ried et al., 2008 (2)  10  503  −4.6 ± 2.8  —  —  11  567  −2.4 ± 2.5  —  — 
  221  —  −8.4 ± 2.8  —  127  —  −7.3 ± 1.5  — 
  282  —  —  −2.3 ± 2.3  440  —  —  −0.1 ± 1.3 
Ried (this article)  19  908  −5.1 ± 2.2  —  —  20  972  −2.6 ± 1.6  —  — 
  10  440  —  −8.7 ± 2.2  —  257  —  −6.1 ± 1.3  — 
  11  468  —  —  −1.5 ± 1.9  14  641  —  —  −0.4 ± 1.2 

SBP difference (garlic vs. placebo), mm HgDBP difference (garlic vs. placebo), mm Hg
Authors, year (reference)Trials, nSubjects, nAllHypertensive subgroupNormotensive subgroupTrials, nSubjects, nAllHypertensive subgroupNormotensive subgroup
Silagy and Neil, 1994 (13)  347  −7.7 ± 3.4  —  —  347  −5.0 ± 2.1  —  — 
  87    −11.1 ± 6.1  —  87    −6.5 ± 3.1  — 
Reinhart et al., 2008 (14)  10  444  −3.9 ± 4.4  —  —  10  444  −2.8 ± 2.4  —  — 
  139    −16.3 ± 10.1  —  139  —  −9.3 ± 4.0  — 
  305    —  −0.5 ± 2.6  305  —  —  −0.9 ± 1.8 
Ried et al., 2008 (2)  10  503  −4.6 ± 2.8  —  —  11  567  −2.4 ± 2.5  —  — 
  221  —  −8.4 ± 2.8  —  127  —  −7.3 ± 1.5  — 
  282  —  —  −2.3 ± 2.3  440  —  —  −0.1 ± 1.3 
Ried (this article)  19  908  −5.1 ± 2.2  —  —  20  972  −2.6 ± 1.6  —  — 
  10  440  —  −8.7 ± 2.2  —  257  —  −6.1 ± 1.3  — 
  11  468  —  —  −1.5 ± 1.9  14  641  —  —  −0.4 ± 1.2 

1

Values are means ± SEs unless otherwise indicated. DBP, diastolic blood pressure; SBP, systolic blood pressure.

TABLE 3

Comparison of meta-analyses on the effect of garlic on blood pressure1

SBP difference (garlic vs. placebo), mm HgDBP difference (garlic vs. placebo), mm Hg
Authors, year (reference)Trials, nSubjects, nAllHypertensive subgroupNormotensive subgroupTrials, nSubjects, nAllHypertensive subgroupNormotensive subgroup
Silagy and Neil, 1994 (13)  347  −7.7 ± 3.4  —  —  347  −5.0 ± 2.1  —  — 
  87    −11.1 ± 6.1  —  87    −6.5 ± 3.1  — 
Reinhart et al., 2008 (14)  10  444  −3.9 ± 4.4  —  —  10  444  −2.8 ± 2.4  —  — 
  139    −16.3 ± 10.1  —  139  —  −9.3 ± 4.0  — 
  305    —  −0.5 ± 2.6  305  —  —  −0.9 ± 1.8 
Ried et al., 2008 (2)  10  503  −4.6 ± 2.8  —  —  11  567  −2.4 ± 2.5  —  — 
  221  —  −8.4 ± 2.8  —  127  —  −7.3 ± 1.5  — 
  282  —  —  −2.3 ± 2.3  440  —  —  −0.1 ± 1.3 
Ried (this article)  19  908  −5.1 ± 2.2  —  —  20  972  −2.6 ± 1.6  —  — 
  10  440  —  −8.7 ± 2.2  —  257  —  −6.1 ± 1.3  — 
  11  468  —  —  −1.5 ± 1.9  14  641  —  —  −0.4 ± 1.2 

SBP difference (garlic vs. placebo), mm HgDBP difference (garlic vs. placebo), mm Hg
Authors, year (reference)Trials, nSubjects, nAllHypertensive subgroupNormotensive subgroupTrials, nSubjects, nAllHypertensive subgroupNormotensive subgroup
Silagy and Neil, 1994 (13)  347  −7.7 ± 3.4  —  —  347  −5.0 ± 2.1  —  — 
  87    −11.1 ± 6.1  —  87    −6.5 ± 3.1  — 
Reinhart et al., 2008 (14)  10  444  −3.9 ± 4.4  —  —  10  444  −2.8 ± 2.4  —  — 
  139    −16.3 ± 10.1  —  139  —  −9.3 ± 4.0  — 
  305    —  −0.5 ± 2.6  305  —  —  −0.9 ± 1.8 
Ried et al., 2008 (2)  10  503  −4.6 ± 2.8  —  —  11  567  −2.4 ± 2.5  —  — 
  221  —  −8.4 ± 2.8  —  127  —  −7.3 ± 1.5  — 
  282  —  —  −2.3 ± 2.3  440  —  —  −0.1 ± 1.3 
Ried (this article)  19  908  −5.1 ± 2.2  —  —  20  972  −2.6 ± 1.6  —  — 
  10  440  —  −8.7 ± 2.2  —  257  —  −6.1 ± 1.3  — 
  11  468  —  —  −1.5 ± 1.9  14  641  —  —  −0.4 ± 1.2 

1

Values are means ± SEs unless otherwise indicated. DBP, diastolic blood pressure; SBP, systolic blood pressure.

Despite the general medical advice, evidence is weak for garlic supplements, including GP, GO, and AGE, to cause harmful interactions if taken in addition to blood-thinning, blood sugar–regulating, or anti-inflammatory medications (36, 46, 47). Physicians and patients need to be mindful, however, of a potentially harmful interaction of garlic with protease inhibitors in antiretroviral therapy (46).

Other cardiovascular-protective effects of garlic

Effect of garlic on cholesterol.

Several meta-analyses demonstrated a cholesterol-lowering effect of garlic supplements. A recent and most comprehensive meta-analysis including 39 trials and almost 2300 subjects suggested that garlic moderately but significantly lowers total serum cholesterol (−17 ± 6 mg/dL) and LDL cholesterol (9 ± 6 mg/dL) if taken for >2 mo by patients with slightly elevated cholesterol (>200 mg/dL, >5.5 mmol/L) (3). The 8% reduction in serum cholesterol is of clinical relevance and has been associated with a 38% risk reduction in coronary events at age 50 y (48, 49). Trials in the meta-analysis used GP (n = 31), GO (n = 6), AGE (n = 6), and raw garlic (n = 3). Nine of the trials ran between 2 and 8 wk, and 30 trials lasted >8 wk.

Side effects with garlic supplements were minimal, with one-third of participants complaining about odor and 7% experiencing mild gastrointestinal discomfort (3). In comparison, mild gastrointestinal complaints were also described by 7% in the placebo group. In contrast, current standard pharmacologic treatment for cholesterol with statins may trigger adverse effects in a considerable number of patients, including myalgia (muscle pain), muscle weakness, neuropathy, cognitive impairment, mood disorders, anxiety, and an increased risk of diabetes (50–53).

Cholesterol is essential for normal body functions that include preserving the integrity of cell membranes, facilitating cell signaling, maintaining the myelin sheath, and synthesizing steroid hormones, vitamin D, and coenzyme Q10. The inhibition of cholesterol synthesis by statin drugs may interfere with these essential pathways, resulting in detrimental effects for some patients (50–53).

In addition, there is cumulative evidence to suggest that lipoproteins also have a role in the immune response to infection as part of the innate immune system (54). Although HDL cholesterol plays a role in the immune response to viral and parasitic infections, LDL cholesterol appears to be involved in the host defense to bacterial infections (54). Oxidized LDL cholesterol, on the other hand, has been associated with plaque formation and increased risk of heart attack and stroke when accumulated in the endothelium (55). The oxidization of LDL cholesterol may be generated by free radicals through dietary factors, such as consumption of trans fats, deep-fried foods, smoking, or the presence of high blood sugar (56). However, chemical analyses have found oxidized LDL cholesterol to consist of many heterogeneous components, suggesting multiple origins, possibly including interaction with pathogens and their toxins (57).

Because of the many purposes of cholesterol and serum lipoproteins in the human body, some of which are undoubtedly still incompletely understood, cholesterol concentrations need to be adjusted with care. Indeed, there is a growing list of clinical trials in which interference with serum cholesterol led to disappointing—and in some cases detrimental—results (58).

In contrast, garlic supplements have been linked to moderate reduction in cholesterol concentrations, therefore providing an alternative cholesterol-regulating agent with a higher safety profile than statins in patients with slightly elevated cholesterol.

Effect of garlic on immunity.

Historically, garlic has been used for its anti-infective activities, immune-boosting properties, and general strengthening actions (1). In vitro and cell culture studies showed garlic to have antibacterial, antivirus, antifungal, and antiparasitic properties. Garlic was shown to stall growth of food pathogens such as Salmonella, Listeria, Escherichia coli, the stomach bacteria Helicobacter pylori, and the tuberculosis-causing pathogen Mycobacterium tuberculosis (59, 60). In addition, garlic inhibits biofilm formation by bacterial pathogens from burn wounds (61). Garlic's antiviral actions include the human rhinovirus, cytomegalovirus, herpes simplex, and influenza (62). Garlic is effective in the treatment of common yeast and fungal infections such as Candida albicans and Aspergillus flavus (63). Furthermore, garlic shows promise as an antiparasitic agent, helping in the treatment of Cryptosporidium, Toxoplasma, Giardia, and Plasmodium (64).

Garlic is a prebiotic, containing fructans and oligosaccharides, which stimulate the growth of “friendly” bacteria in the digestive tract (65, 66) that in turn make up the microbiome, which contributes to ∼80% of the immune system (67). Garlic was shown to stimulate activation of the humoral and inert immune system, including the activation of macrophages by NO production and T and B cell production (68–70).

Clinical trials have shown garlic to have a beneficial effect in the prevention, duration, and severity of upper respiratory infections. A randomized, double-blind, placebo-controlled trial in 146 participants testing the effect of 180 mg GP/d over 3 mo found a 37% reduction in the number of colds (garlic compared with placebo: n = 24 compared with n = 65; P < 0.001) and a 30% reduction in the duration of illness (garlic compared with placebo: 1.5 compared with 5 d; P < 0.001) in the group taking garlic compared with the placebo group (71).

A recent trial in 120 participants that tested the effect of 2.56 g AGE/d over 3 mo found a 61% reduction in the number of days (garlic compared with placebo: 53 compared with 126 d; P < 0.001) and a 21% reduction in symptoms (garlic compared with placebo: 584 compared with 126; P < 0.001) (70). In this trial, a significant increase in γδ-T cells (P = 0.039) and NK cells (P = 0.043) was shown in the garlic group after 45 d compared with placebo.

In addition, garlic contains the immunomodulatory proteins lectins or agglutinins [allium sativum agglutinin (ASA) I and ASA II] (66, 72). Furthermore, garlic was shown to reduce inflammatory markers, including C-reactive protein and TNF-α (73, 74). A high concentration of inflammatory C-reactive protein has been associated with greater odds of developing coronary artery disease (OR: 1.45; 95% CI: 1.25, 1.68) (75). Therefore, the beneficial effects of garlic on the immune system, including C-reactive protein and cytokines such as ILs and TNF-α, are also associated with improved cardiovascular health.

In conclusion, garlic has the potential to improve cardiovascular health on several levels. First, there is consistent evidence that garlic supplements lower blood pressure in hypertensive individuals. Second, there is strong evidence that garlic modulates cholesterol concentrations when slightly elevated. Third, garlic has several immune system–enhancing properties that directly and indirectly benefit cardiovascular health. Garlic supplements have a high safety profile and are generally well tolerated. Therefore, garlic supplements may be considered as an alternative or complementary treatment in addition to standard medication for cardiovascular health. Further long-term trials are needed to elucidate the effect of garlic supplementation on cardiovascular morbidity and mortality.

Acknowledgments

The sole author read and approved the final version of the manuscript.

References

1

Rivlin

RS

.

Historical perspective on the use of garlic

.

J Nutr

2001

;

131

(

Suppl

):

951S

4S

.

2

Ried

K

,

Frank

OR

,

Stocks

NP

,

Fakler

P

,

Sullivan

T

.

Effect of garlic on blood pressure: a systematic review and meta-analysis

.

BMC Cardiovasc Disord

2008

;

8

:

13

.

3

Ried

K

,

Toben

C

,

Fakler

P

.

Effect of garlic on serum lipids: an updated meta-analysis

.

Nutr Rev

2013

;

71

:

282

99

.

4

Lawes

CM

,

Vander Hoorn

S

,

Rodgers

A

.

Global burden of blood-pressure-related disease, 2001

.

Lancet

2008

;

371

:

1513

8

.

5

Martiniuk

AL

,

Lee

CM

,

Lawes

CM

,

Ueshima

H

,

Suh

I

,

Lam

TH

,

Gu

D

,

Feigin

V

,

Jamrozik

K

,

Ohkubo

T

, et al. 

Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region

.

J Hypertens

2007

;

25

:

73

9

.

6

Lewington

S

,

Clarke

R

,

Qizilbash

N

,

Peto

R

,

Collins

R

.

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

.

Lancet

2002

;

360

:

1903

13

.

7

Centers for Disease Control and Prevention

.

Vital signs: prevalence, treatment, and control of hypertension–United States, 1999–2002 and 2005–2008

.

MMWR Morb Mortal Wkly Rep

2011

;

60

:

103

.

8

Chobanian

AV

,

Bakris

GL

,

Black

HR

,

Cushman

WC

,

Green

LA

,

Izzo

JL

Jr
,

Jones

DW

,

Materson

BJ

,

Oparil

S

,

Wright

JT

Jr
, et al. 

The 7th Report of the Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure

.

JAMA

2003

;

289

:

2560

72

.

9

Briganti

EM

,

Shaw

JE

,

Chadban

SJ

,

Zimmet

PZ

,

Welborn

TA

,

McNeil

JJ

,

Atkins

RC

.

Untreated hypertension among Australian adults: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study

.

Med J Aust

2003

;

179

:

135

9

.

10

Hobbs

F

,

Irwin

P

,

Rubner

J

.

Evidence-based treatment of hypertension: what's the role of angiotensin II receptor blockers?

Br J Cardiol.

2005

;

12

:

65

70

.

11

Simons

LA

,

Ortiz

M

,

Calcino

G

.

Persistence with antihypertensive medication: Australia-wide experience, 2004–2006

.

Med J Aust

2008

;

188

:

224

7

.

12

Olsen

H

,

Klemetsrud

T

,

Stokke

HP

,

Tretli

S

,

Westheim

A

.

Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway

.

Blood Press

1999

;

8

:

94

101

.

13

Silagy

CA

,

Neil

HA

.

A meta-analysis of the effect of garlic on blood pressure

.

J Hypertens

1994

;

12

:

463

8

.

14

Reinhart

KM

,

Coleman

CI

,

Teevan

C

,

Vachhani

P

,

White

CM

.

Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis

.

Ann Pharmacother

2008

;

42

:

1766

71

.

15

Amagase

H

.

Clarifying the real bioactive constituents of garlic

.

J Nutr

2006

;

136

(

Suppl

):

716S

25S

.

16

Al-Qattan

KK

,

Thomson

M

,

Al-Mutawa'a

S

,

Al-Hajeri

D

,

Drobiova

H

,

Ali

M

.

Nitric oxide mediates the blood-pressure lowering effect of garlic in the rat two-kidney, one-clip model of hypertension

.

J Nutr

2006

;

136

(

Suppl

):

774S

6S

.

17

Benavides

GA

,

Squadrito

GL

,

Mills

RW

,

Patel

HD

,

Isbell

TS

,

Patel

RP

,

Darley-Usmar

VM

,

Doeller

JE

,

Kraus

DW

.

Hydrogen sulfide mediates the vasoactivity of garlic

.

Proc Natl Acad Sci USA

2007

;

104

:

17977

82

.

18

Coletta

C

,

Papapetropoulos

A

,

Erdelyi

K

,

Olah

G

,

Módis

K

,

Panopoulos

P

,

Asimakopoulou

A

,

Gerö

D

,

Sharina

I

,

Martin

E

.

Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation

.

Proc Natl Acad Sci USA

2012

;

109

:

9161

6

.

19

Suetsuna

K

.

Isolation and characterization of angiotensin I-converting enzyme inhibitor dipeptides derived from Allium sativum L (garlic)

.

J Nutr Biochem

1998

;

9

:

415

9

.

20

Kim-Park

S

,

Ku

DD

.

Garlic elicits a nitric oxide-dependent relaxation and inhibits hypoxic pulmonary vasoconstriction in rats

.

Clin Exp Pharmacol Physiol

2000

;

27

:

780

6

.

21

http://www.ncbi.nlm.nih.gov/pmc/tools/stylechecker/

Review Manager (RevMan)

[computer program]. Version 5.2.

Copenhagen (Denmark)

:

The Nordic Cochrane Centre, The Cochrane Collaboration

;

2012

.

22

Kandziora

J

.

Blutdruck- und lipidsenkende Wirkung eines Knoblauch-Präparates in Kombination mit einem Diuretikum (study 1). [Blood pressure and lipid reducing effect of a garlic supplement in combination with a diuretic (Study 1).]

Arztl Forsch

1988

;

35

:

3

8

(in German).

23

Auer

W

,

Eiber

A

,

Hertkorn

E

,

Hoehfeld

E

,

Koehrle

U

,

Lorenz

A

,

Mader

F

,

Merx

W

,

Otto

G

,

Schmid-Otto

B

, et al. 

Hypertension and hyperlipidaemia: garlic helps in mild cases

.

Br J Clin Pract Suppl

1990

;

69

:

3

6

.

24

Vorberg

G

,

Schneider

B

.

Therapy with garlic: results of a placebo-controlled, double-blind study

.

Br J Clin Pract Suppl

1990

;

69

:

7

11

.

25

Holzgartner

H

,

Schmidt

U

,

Kuhn

U

.

Comparison of the efficacy and tolerance of a garlic preparation vs. bezafibrate

.

Arzneimittelforschung

1992

;

42

:

1473

7

.

26

Jain

AK

,

Vargas

R

,

Gotzkowsky

S

,

McMahon

FG

.

Can garlic reduce levels of serum lipids? A controlled clinical study

.

Am J Med

1993

;

94

:

632

5

.

27

Santos

OSDeA

,

Gruenwald

J

.

Effect of garlic powder tablets on blood lipids and blood pressure: a six-month placebo-controlled, double-blind study

.

Br J Clin Res

1993

;

4

:

37

44

.

28

Kiesewetter

H

,

Jung

F

,

Jung

EM

,

Blume

J

,

Mrowietz

C

,

Birk

A

,

Koscielny

J

,

Wenzel

E

.

Effects of garlic coated tablets in peripheral arterial occlusive disease

.

Clin Investig

1993

;

71

:

383

6

.

29

Saradeth

T

,

Seidl

S

,

Resch

K

,

Ernst

E

.

Does garlic alter the lipid pattern in normal volunteers?

Phytomedicine

1994

;

1

:

183

5

.

30

Simons

LA

,

Balasubramaniam

S

,

von Konigsmark

M

,

Parfitt

A

,

Simons

J

,

Peters

W

.

On the effect of garlic on plasma lipids and lipoproteins in mild hypercholesterolaemia

.

Atherosclerosis

1995

;

113

:

219

25

.

31

Steiner

M

,

Khan

AH

,

Holbert

D

,

Lin

RI

.

A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids

.

Am J Clin Nutr

1996

;

64

:

866

70

.

32

Adler

AJ

,

Holub

B

.

Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men

.

Am J Clin Nutr

1997

;

65

:

445

50

.

33

Isaacsohn

J

,

Moser

M

,

Stein

E

,

Dudley

K

,

Davey

J

,

Liskov

E

,

Black

H

.

Garlic powder and plasma lipids and lipoproteins: a multicenter, randomized, placebo-controlled trial

.

Arch Intern Med

1998

;

158

:

1189

94

.

34

Zhang

XH

,

Lowe

D

,

Giles

P

,

Fell

S

,

Board

AR

,

Baughan

JA

,

Connock

MJ

,

Maslin

DJ

.

A randomized trial of the effects of garlic oil upon coronary heart disease risk factors in trained male runners

.

Blood Coagul Fibrinolysis

2001

;

12

:

67

74

.

35

Williams

MJ

,

Sutherland

WH

,

McCormick

MP

,

Yeoman

DJ

,

de Jong

SA

.

Aged garlic extract improves endothelial function in men with coronary artery disease

.

Phytother Res

2005

;

19

:

314

9

.

36

Macan

H

,

Uykimpang

R

,

Alconcel

M

,

Takasu

J

,

Razon

R

,

Amagase

H

,

Niihara

Y

.

Aged garlic extract may be safe for patients on warfarin therapy

.

J Nutr

2006

;

136

(

Suppl

):

793S

5S

.

37

Sobenin

IA

,

Andrianova

IV

,

Demidova

ON

,

Gorchakova

T

,

Orekhov

AN

.

Lipid-lowering effects of time-released garlic powder tablets in double-blinded placebo-controlled randomized study

.

J Atheroscler Thromb

2008

;

15

:

334

8

.

38

Sobenin

IA

,

Andrianova

IV

,

Fomchenkov

IV

,

Gorchakova

TV

,

Orekhov

AN

.

Time-released garlic powder tablets lower systolic and diastolic blood pressure in men with mild and moderate arterial hypertension

.

Hypertens Res

2009

;

32

:

433

7

.

39

Ried

K

,

Frank

OR

,

Stocks

NP

.

Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomised controlled trial

.

Maturitas

2010

;

67

:

144

50

.

40

Ried

K

,

Frank

OR

,

Stocks

NP

.

Aged garlic extract reduces blood pressure in hypertensives: a dose-response trial

.

Eur J Clin Nutr

2013

;

67

:

64

70

.

41

Nakasone

Y

,

Nakamura

Y

,

Yamamoto

T

,

Yamaguchi

H

.

Effect of a traditional Japanese garlic preparation on blood pressure in prehypertensive and mildly hypertensive adults

.

Exp Ther Med

2013

;

5

:

399

405

.

42

Beck

E

,

Gruenwald

J

.

Allium sativum in der Stufentherapie der Hyperlipidaemie. [Allium sativum for step-therapy in hyperlipidemia.]

Med Welt

1993

;

44

:

516

20

(in German).

43

Borrelli

F

,

Capasso

R

,

Izzo

AA

.

Garlic (Allium sativum L.): adverse effects and drug interactions in humans

.

Mol Nutr Food Res

2007

;

51

:

1386

97

.

44

Waring

RH

,

Klovrza

LZ

,

Harris

RM

.

Diet and individuality in detoxification

.

J Nutr Environ Med

2007

;

16

:

95

105

.

45

Meletis

CD

.

Cleansing of the human body: a daily essential process

.

Altern Complement Ther

2001

;

7

:

196

202

.

46

Izzo

AA

,

Ernst

E

.

Interactions between herbal medicines and prescribed drugs: an updated systematic review

.

Drugs

2009

;

69

:

1777

98

.

47

Harauma

A

,

Moriguchi

T

.

Aged garlic extract improves blood pressure in spontaneously hypertensive rats more safely than raw garlic

.

J Nutr

2006

;

136

(

Suppl

):

769S

73S

.

48

Law

MR

,

Wald

NJ

,

Thompson

SG

.

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

BMJ

1994

;

308

:

367

72

.

49

Wald

NJ

,

Law

MR

.

Serum cholesterol and ischaemic heart disease

.

Atherosclerosis

1995

;

118

(

Suppl

):

S1

5

.

50

Tatley

M

,

Savage

R

.

Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents

.

Drug Saf

2007

;

30

:

195

201

.

51

Golomb

BA

,

Evans

MA

.

Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism

.

Am J Cardiovasc Drugs

2008

;

8

:

373

418

.

52

Sattar

N

,

Preiss

D

,

Murray

HM

,

Welsh

P

,

Buckley

BM

,

de Craen

AJ

,

Seshasai

SR

,

McMurray

JJ

,

Freeman

DJ

,

Jukema

JW

, et al. 

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

.

Lancet

2010

;

375

:

735

42

.

53

Preiss

D

,

Sattar

N

.

Statins and the risk of new-onset diabetes: a review of recent evidence

.

Curr Opin Lipidol

2011

;

22

:

460

6

.

54

Han

R

.

Plasma lipoproteins are important components of the immune system

.

Microbiol Immunol

2010

;

54

:

246

53

.

55

Willcox

JK

,

Catignani

GL

,

Lazarus

S

.

Tomatoes and cardiovascular health

.

Crit Rev Food Sci Nutr

2003

;

43

:

1

18

.

56

Willcox

JK

,

Ash

SL

,

Catignani

GL

.

Antioxidants and prevention of chronic disease

.

Crit Rev Food Sci Nutr

2004

;

44

:

275

95

.

57

Parthasarathy

S

,

Raghavamenon

A

,

Garelnabi

MO

,

Santanam

N

.

Oxidized low-density lipoprotein

.

Methods Mol Biol

2010

;

610

:

403

17

.

58

Filippatos

TD

,

Elisaf

MS

.

High density lipoprotein and cardiovascular diseases

.

World J Cardiol.

2013

;

5

:

210

.

59

Kumar

M

,

Berwal

J

.

Sensitivity of food pathogens to garlic (Allium sativum)

.

J Appl Microbiol

1998

;

84

:

213

5

.

60

Sivam

GP

.

Protection against Helicobacter pylori and other bacterial infections by garlic

.

J Nutr

2001

;

131

(

Suppl

):

1106S

8S

.

61

Nidadavolu

P

,

Amor

W

,

Tran

PL

,

Dertien

J

,

Colmer-Hamood

JA

,

Hamood

AN

.

Garlic ointment inhibits biofilm formation by bacterial pathogens from burn wounds

.

J Med Microbiol

2012

;

61

:

662

71

.

62

Tsai

Y

,

Cole

LL

,

Davis

LE

,

Lockwood

SJ

,

Simmons

V

,

Wild

GC

.

Antiviral properties of garlic: in vitro effects on influenza B, herpes simplex and coxsackie viruses

.

Planta Med

1985

;

51

:

460

1

.

63

Davis

SR

.

An overview of the antifungal properties of allicin and its breakdown products—the possibility of a safe and effective antifungal prophylactic

.

Mycoses

2005

;

48

:

95

100

.

64

Anthony

J-P

,

Fyfe

L

,

Smith

H

.

Plant active components—a resource for antiparasitic agents?

Trends Parasitol

2005

;

21

:

462

8

.

65

Roberfroid

MB

.

Prebiotics and probiotics: are they functional foods?

Am J Clin Nutr

2000

;

71

(

Suppl

):

1682S

7S

.

66

Chandrashekar

PM

,

Prashanth

KVH

,

Venkatesh

YP

.

Isolation, structural elucidation and immunomodulatory activity of fructans from aged garlic extract

.

Phytochemistry

2011

;

72

:

255

64

.

67

Furness

JB

,

Kunze

WA

,

Clerc

N

.

Nutrient tasting and signalling mechanisms in the gut. II. The intestine as a sensory organ: neural, endocrine, and immune responses

.

Am J Physiol

1999

;

277

:

G922

8

.

68

Abdullah

T

,

Kirkpatrick

D

,

Carter

J

.

Enhancement of natural killer cell activity in AIDS patients

.

DZ Onkologie

1989

;

21

:

52

3

.

69

Brosche

T

,

Platt

N

.

Knoblauchtherapie und zellulaere Immunabwehr im Alter. [Garlic therapy and cellular immunocompetence in the elderly.]

Z Phytother

1994

;

15

:

23

4

(in German).

70

Nantz

MP

,

Rowe

CA

,

Muller

CE

,

Creasy

RA

,

Stanilka

JM

,

Percival

SS

.

Supplementation with aged garlic extract improves both NK and γδ-T cell function and reduces the severity of cold and flu symptoms: a randomized, double-blind, placebo-controlled nutrition intervention

.

Clin Nutr

2012

;

31

:

337

44

.

71

Josling

P

.

Preventing the common cold with a garlic supplement: a double-blind, placebo-controlled survey

.

Adv Ther

2001

;

18

:

189

93

.

72

Chandrashekar

PM

,

Venkatesh

Y

.

Identification of the protein components displaying immunomodulatory activity in aged garlic extract

.

J Ethnopharmacol

2009

;

124

:

384

90

.

73

Zeb

I

,

Ahmadi

N

,

Nasir

K

,

Kadakia

J

,

Larijani

VN

,

Flores

F

,

Li

D

,

Budoff

MJ

.

Aged garlic extract and coenzyme Q10 have favorable effect on inflammatory markers and coronary atherosclerosis progression: a randomized clinical trial

.

J Cardiovasc Dis Res

2012

;

3

:

185

90

.

74

Mozaffari-Khosravi

H

,

Hesabgar

H-a-S

,

Owlia

M-B

,

Hadinedoushan

H

,

Barzegar

K

,

Fllahzadeh

MH

.

The effect of garlic tablet on pro-inflammatory cytokines in postmenopausal osteoporotic women: a randomized controlled clinical trial

.

J Diet Suppl

2012

;

9

:

262

71

.

75

Danesh

J

,

Wheeler

JG

,

Hirschfield

GM

,

Eda

S

,

Eiriksdottir

G

,

Rumley

A

,

Lowe

GD

,

Pepys

MB

,

Gudnason

V

.

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

.

N Engl J Med

2004

;

350

:

1387

97

.

Abbreviations

     
  • AGE

  •  
  • ASA

    allium sativum agglutinin

  •  
  • DBP

  •  
  • GO

  •  
  • GP

  •  
  • SBP

Author notes

1

Published in a supplement to The Journal of Nutrition. Presented at the conference "2014 International Garlic Symposium: Role of Garlic in Cardiovascular Disease Prevention, Metabolic Syndrome, and Immunology," held 4–6 March 2014 at St. Regis Monarch Beach Resort in Dana Point, CA. This supplement is dedicated to our colleague and friend John A Milner. His dedication to good science and his voice for nutrition are remembered and sorely missed. The symposium was sponsored by the University of California, Los Angeles School of Medicine and the University of Florida and co-sponsored by the American Botanical Council; the American Herbal Products Association; the ASN; the Japanese Society for Food Factors; the Japan Society for Bioscience, Biotechnology, and Agrochemistry; the Japan Society of Nutrition and Food Science; and the Natural Products Association. The symposium was supported by Agencias Motta S.A.; Bionam; Eco-Nutraceuticos; Healthy U 2000 Ltd.; Magna; Mannavita Bvba; MaxiPharma; Medica Nord A.S.; Nature's Farm Pte. Ltd.; Nature Valley W.L.L.; Organic Health Ltd.; Oy Valioravinto Ab; Purity Life Health Products L.P.; PT Nutriprima Jayasakti; Vitaco Health Ltd.; Vitae Natural Nutrition; Sanofi Consumer Health Care; Wakunaga Pharmaceutical Co., Ltd.; and Wakunaga of America Co., Ltd. The Chair of the conference and Scientific Program Coordinator for the supplement publication was Matthew J Budoff, Harbor-UCLA Medical Center, Torrance, CA. Scientific Program Coordinator disclosures: MJ Budoff has been awarded research grants from Wakunaga of America Co., Ltd., and received an honorarium for serving as Chair of the conference. Vice-Chair and Supplement Coordinator for the supplement publication was Susan S Percival, University of Florida, Gainesville, FL. Supplement Coordinator disclosures: SS Percival has been awarded research grants from Wakunaga of America Co., Ltd., and received an honorarium for serving as Vice-Chair of the conference. Publication costs for this supplement were defrayed in part by the payment of page charges. This publication must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact. The opinions expressed in this publication are those of the authors and are not attributable to the sponsors or the publisher, Editor, or Editorial Board of The Journal of Nutrition.

© 2016 American Society for Nutrition

© 2016 American Society for Nutrition

Citations

Views

Altmetric

Email alerts

More on this topic

Citing articles via

  • Latest

  • Most Read

  • Most Cited

More from Oxford Academic

How much garlic should I take for high blood pressure?

So far, this report has provided the following garlic doses for treating hypertension: 188mg of garlic powder mixed with egg-yolk taken daily for twelve weeks. 400mg of raw garlic taken daily for six months. 240-2,400mg of aged garlic extract a day for two to twenty-three weeks.

How long does it take for aged garlic to work?

The natural aging process that can take up to 20 months, converts the harsh unstable organosulfur properties in garlic into stable bioavailable compounds with numerous health properties.

Is Kyolic garlic good for blood pressure?

Garlic supplements have shown effectiveness in reducing blood pressure in hypertensive patients, similarly to first-line standard anti-hypertensive medications. Kyolic garlic has also shown promise in improving cardiovascular health by reducing arterial stiffness, elevated cholesterol levels and blood 'stickiness'.

Does raw garlic reduce high blood pressure?

Garlic has been linked to improved cardiovascular health. Garlic has been suggested to lower blood pressure, plasma lipids as well as an antiplatelet effect and other cardiovascular markers.